3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(4-hydroxycarbamoylpiperidin-4-yl)-amino]propionic acid ethyl ester

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(4-hydroxycarbamoylpiperidin-4-yl)-amino]propionic acid ethyl ester
• 英文别名: Ethyl 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[4-(hydroxycarbamoyl)piperidin-4-yl]amino]propanoate
• 化学式: C₂₃H₂₈FN₃O₇S
• 分子量: 509.556
• InChiKey: SQVMVVWWXDFCJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  143
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders
  申请人：Pfizer Products Inc.

  公开号：EP1088550A1

  公开（公告）日：2001-04-04

  The present invention relates to a method of using a compound of the formula (I): wherein A, X1, X2, and Q are as defined herein, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the treatment of a disease, condition or disorder of the peripheral or central nervous system, including but not limited to Alzheimer's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, migraine, cerebral amyloid angiopathy, AIDS, age-related cognitive decline, mild cognitive impairment and prion diseases.

  本发明涉及一种使用式（I）化合物的方法： 其中 A、X1、X2 和 Q 如本文所定义，其药学上可接受的盐，或其药物组合物，用于治疗外周或中枢神经系统的疾病、病症或紊乱，包括但不限于阿尔茨海默病、中风/脑缺血、头部创伤、脊髓损伤、多发性硬化症、肌萎缩性脊髓侧索硬化症、亨廷顿氏病、帕金森氏病、偏头痛、脑淀粉样血管病、艾滋病、老年性认知功能衰退、轻度认知功能障碍和朊病毒疾病。
• Aryloxyarylsulfonylamino hydroxamic acid derivatives
  申请人：Pfizer Products Inc.

  公开号：EP1415984A1

  公开（公告）日：2004-05-06

  A compound of the formula (I) or the pharmaceutically acceptable salts thereof, wherein R1 is (C1-C6)alkyl; R2 is (C1-C6)alkyl; or R1 and R2 taken together with the carbon atom to which they are attached form a ring selected from (C5-C7)cycloalkyl, 4-tetrahydropyranyl and 4-piperidinyl; R3 is hydrogen or (C1-C6)alkyl; and Y is a substituent of any of the carbon atoms of the phenyl ring capable of supporting an additional bond, independently selected from hydrogen, fluoro, chloro, trifluoromethyl, (C1-C6)alkoxy, trifluoromethoxy, difluoromethoxy and (C1-C6)alkyl.

  一种式(I)化合物或其药学上可接受的盐，其中 R1 是(C1-C6)烷基；R2 是(C1-C6)烷基；或 R1 和 R2 与它们所连接的碳原子一起形成选自(C5-C7)环烷基、4-四氢吡喃基和 4-哌啶基的环；R3 是氢或(C1-C6)烷基；以及 Y 是苯基环上任何一个碳原子的取代基，该取代基能够支持一个额外的键，独立选自氢、氟、氯、三氟甲基、(C1-C6)烷氧基、三氟甲氧基、二氟甲氧基和(C1-C6)烷基。
• ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES
  申请人：Pfizer Products Inc.

  公开号：EP1003720B1

  公开（公告）日：2004-03-31
• US6214872B1
  申请人：——

  公开号：US6214872B1

  公开（公告）日：2001-04-10
• US6417229B1
  申请人：——

  公开号：US6417229B1

  公开（公告）日：2002-07-09